SCARF2 Antibody

What is SCARF2 and how does it differ from SCARF1?

SCARF2 is a scavenger receptor expressed by endothelial cells with very large cytoplasmic domains, also known as SREC-2 (scavenger receptor expressed by endothelial cells 2). It represents the second isotype in the SREC family, with the cDNA for murine SCARF2 showing approximately 35% homology to SCARF1 .

The critical functional difference between these proteins lies in their ligand binding abilities. While SCARF1 (SREC-1) plays an important role in binding and endocytosis of various endogenous and exogenous ligands, including modified low-density lipoprotein (LDL), SCARF2 does not possess this same activity . This functional distinction has been experimentally confirmed using SCARF1-SCARF2 chimeras, demonstrating that key residues conferring ligand binding in SCARF1 are not conserved in SCARF2 .

SCARF2 has been implicated in Vanden Ende-Gupta syndrome (VDEGS), with homozygous mutations in the SCARF2 gene identified as the root cause . Additionally, recent research shows that SCARF2 expression is significantly elevated in glioblastoma compared to normal brain tissue, suggesting a potential role in cancer pathogenesis .

What applications are validated for SCARF2 antibodies in research?

SCARF2 antibodies have been validated for several key research applications:

• Western Blot (WB): Typically used at 1:1000 dilution to detect SCARF2 protein (calculated MW: 92.4 kDa) in cell and tissue lysates. This approach has successfully demonstrated increased SCARF2 expression in glioblastoma tissues compared to normal brain tissues .

• Flow Cytometry (FCM): Recommended at 1:10-1:50 dilution for analyzing SCARF2 expression in cell populations, particularly useful for quantifying expression differences between normal and cancerous cells .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of SCARF2 protein in solution-based assays .

• Immunohistochemistry (IHC): Successfully employed to compare SCARF2 expression between normal brain tissue and glioblastoma samples, revealing significantly higher expression in tumor tissues .

• Immunofluorescence: Utilized for subcellular localization studies, which have revealed that SCARF2 is present in both the cytoplasm and nucleus of glioblastoma cells .

These applications require careful optimization of antibody concentration, incubation conditions, and detection methods to achieve reliable results across different experimental systems.

How should researchers handle and store SCARF2 antibodies for optimal performance?

For maintaining SCARF2 antibody integrity and maximizing experimental reliability, follow these evidence-based handling procedures:

• Storage temperature: Store at -20°C as recommended for commercially available SCARF2 antibodies. The antibody from Abbexa specifically indicates this temperature requirement .

• Aliquoting: Prepare small aliquots upon first thawing to minimize freeze-thaw cycles, which can significantly reduce antibody activity .

• Avoid repeated freeze/thaw cycles: Each cycle potentially degrades antibody quality. This is explicitly noted in product documentation .

• Buffer conditions: Most SCARF2 antibodies are supplied in PBS containing 0.09% sodium azide as a preservative, which helps maintain stability .

• Working dilution preparation: Prepare fresh dilutions on the day of experiments in appropriate buffers (typically PBS with 1-5% BSA or normal serum).

• Temperature considerations during experiments: Keep antibodies cold (on ice or at 4°C) during experimental procedures unless a specific protocol indicates otherwise.

• Quality control: Periodically validate antibody performance using positive control samples with known SCARF2 expression, such as U87-MG glioblastoma cells which have been documented to express elevated levels of SCARF2 .

Following these guidelines will help ensure consistent and reliable results when using SCARF2 antibodies in research applications.

How can researchers validate SCARF2 antibody specificity in brain tumor studies?

Validating SCARF2 antibody specificity is essential for reliable brain tumor research. A comprehensive validation strategy should include:

• Multiple antibody validation approach:

  • Use antibodies from different suppliers targeting distinct SCARF2 epitopes

  • Compare staining patterns and bands to confirm consistency across antibodies

  • Verify detection of the expected molecular weight (approximately 92.4 kDa)

• Genetic validation methods:

  • SCARF2 knockdown or knockout controls using siRNA or CRISPR-Cas9

  • SCARF2 overexpression systems to confirm increased signal intensity

  • Observe corresponding changes in antibody signal intensity that correlate with genetic manipulation

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide (such as the KLH-conjugated synthetic peptide between 826-854 amino acids from the C-terminal region of human SCARF2)

  • Verify elimination or reduction of specific staining

• Cross-reactivity assessment:

  • Test for potential cross-reactivity with SCARF1, which shares 35% homology with SCARF2

  • Include SCARF1-expressing tissues/cells as controls

  • Note that some antibodies may react with both human and mouse SCARF2, so species specificity should be verified

• Correlation with other detection methods:

  • Compare protein detection with mRNA levels by RT-PCR

  • Note that discrepancies between mRNA and protein levels have been observed in GBM cell lines, with protein expression increased despite low mRNA levels

For brain tumor studies specifically, include normal brain tissue controls from cadavers or autopsy samples of surrounding normal brain from glioblastoma patients, as described in published protocols .

What methodological approaches are recommended for studying SCARF2's role in cancer prognosis?

To investigate SCARF2's prognostic significance in cancer, particularly glioblastoma, researchers should implement these methodological approaches:

This multi-faceted approach has successfully demonstrated that SCARF2 expression is elevated in GBM and correlates with poor prognosis, supporting its potential as a diagnostic marker and therapeutic target .

What explains the discrepancy between SCARF2 protein and mRNA levels in glioblastoma?

Research has revealed an intriguing inverse relationship between SCARF2 protein and mRNA expression in glioblastoma that warrants methodological consideration:

How can SCARF1-SCARF2 chimeras be designed to study ligand binding functions?

Designing SCARF1-SCARF2 chimeras represents a sophisticated approach to identify critical domains and residues involved in ligand binding and receptor function:

• Rational design strategy based on structural insights:

  • Create domain swap chimeras focusing on extracellular regions where ligand binding occurs

  • Generate progressive chimeras with increasing proportions of SCARF1 sequence in SCARF2 backbone

  • Target non-conserved residues between SCARF1 and SCARF2 in putative binding interfaces

  • Focus on regions that determine the differential binding of modified LDLs

• Experimental design considerations:

  • Express chimeric constructs in mammalian cells to ensure proper folding and post-translational modifications

  • Include epitope tags that don't interfere with binding function

  • Verify surface expression levels using flow cytometry

  • Normalize binding data to account for expression differences

• Validation approach:

  • Wild-type SCARF1 as positive control for modified LDL binding

  • Wild-type SCARF2 as negative control (naturally lacks binding ability)

  • Dose-response binding studies with fluorescently labeled ligands

  • Competition assays to confirm binding specificity

• Key findings from published research:

  • Chimeric experiments have successfully demonstrated "gain-of-function" by conferring binding of modified LDLs to SCARF2

  • Specific residues in SCARF1 not conserved in SCARF2 have been identified as critical for ligand binding

  • These studies provide mechanistic insight into the functional differences between these related receptors

• Advanced structural analysis:

  • Molecular modeling to predict structural changes in chimeric proteins

  • Structural validation through techniques like hydrogen-deuterium exchange mass spectrometry

  • Correlation of structural features with binding properties

This chimeric approach has proven valuable in understanding the functional divergence between SCARF1 and SCARF2, despite their sequence similarity, and provides a framework for investigating other members of the scavenger receptor family.

What immunohistochemistry protocol optimizations are critical for SCARF2 detection in brain tissue?

For optimal SCARF2 detection in brain tissue sections, researchers should implement these critical protocol modifications:

• Tissue preparation considerations:

  • Use fresh tissue fixed in 10% neutral buffered formalin for 24-48 hours

  • For brain tumor studies, obtain normal brain tissue from cadavers or from surrounding non-tumor areas during surgery

  • Section at 4-5 μm thickness onto positively charged slides

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is crucial

  • Pressure cooker method yields superior results compared to microwave or water bath methods

  • Cool slides gradually to room temperature to prevent tissue detachment

• Blocking and antibody parameters:

  • Block with 5% normal serum corresponding to the secondary antibody host species

  • Anti-SCARF2 antibody concentration typically effective at 1:100-1:200 dilution

  • Extend primary antibody incubation to overnight at 4°C for improved sensitivity

  • Use horseradish peroxidase-conjugated anti-rabbit IgG secondary antibodies for detection

• Signal development and visualization:

  • Develop with DAB chromogen (mixture of Reagent D1, D2, and D3 as described in published protocols)

  • Monitor color development microscopically to optimize signal-to-noise ratio

  • Counterstain with hematoxylin to visualize tissue architecture

• Controls and validation:

  • Include positive control GBM tissue with known SCARF2 expression

  • Use isotype control antibodies matched to the SCARF2 antibody

  • Include normal brain tissue as comparative control

  • Validate findings with Western blot on tissue lysates from the same samples

• Scoring and quantification:

  • Evaluate both intensity and percentage of positive cells

  • Note subcellular localization patterns (SCARF2 has been observed in both cytoplasm and nucleus)

  • Implement standardized scoring systems for consistency across samples

Following this optimized protocol has successfully demonstrated higher SCARF2 expression in brain cancer tissue compared to normal brain tissue in published research .

How should flow cytometry be optimized for quantifying SCARF2 in tumor cells?

For precise quantification of SCARF2 expression in tumor cells using flow cytometry, implement these technical optimizations:

• Sample preparation refinements:

  • Use gentle enzymatic dissociation methods to preserve surface antigen integrity

  • Include viability dye to exclude dead cells which may give false positive signals

  • Filter cell suspensions through 40-70 μm strainers to ensure single-cell analysis

• Antibody selection and titration:

  • Select antibodies validated for flow cytometry applications

  • Perform antibody titration within the recommended range (1:10 - 1:50) to determine optimal concentration

  • Include matched isotype controls at equivalent concentrations

  • Consider fluorochrome brightness when designing panels (PE or APC recommended for potentially low-abundance targets)

• Surface vs. intracellular staining strategy:

  • For complete SCARF2 detection, implement both surface and intracellular staining

  • Research has shown SCARF2 localizes to both cytoplasm and nucleus in GBM cells

  • For intracellular staining, use appropriate fixation (4% paraformaldehyde) and permeabilization (0.1% saponin or Triton X-100)

• Multiparameter panel design:

  • Include markers to identify tumor cells and exclude non-tumor populations

  • Add markers for cell cycle or stemness to correlate with SCARF2 expression

  • Use fluorescence minus one (FMO) controls for accurate gating

• Instrument setup and quality control:

  • Conduct daily calibration with fluorescent beads

  • Implement compensation controls for each fluorochrome

  • Maintain consistent PMT voltages between experiments

• Data analysis optimization:

  • Establish a standardized gating strategy that excludes debris, doublets, and dead cells

  • Report both percentage of positive cells and mean/median fluorescence intensity

  • Compare results to Western blot findings to validate expression patterns

These optimizations will enable reliable quantification of SCARF2 expression differences between normal cells and tumor cells, facilitating investigations into its potential as a diagnostic marker for glioblastoma and other cancers.

What bioinformatic approaches should be used for analyzing SCARF2 in cancer databases?

For comprehensive bioinformatic analysis of SCARF2 expression in cancer, researchers should implement these methodological approaches:

This comprehensive bioinformatic approach has successfully demonstrated SCARF2's potential as a prognostic marker in glioblastoma, with higher expression correlating with poorer patient outcomes .